Epigenomics Ag Stock Fundamentals
| EPGNF Stock | USD 0.79 0.00 0.00% |
Epigenomics AG fundamentals help investors to digest information that contributes to Epigenomics' financial success or failures. It also enables traders to predict the movement of Epigenomics Pink Sheet. The fundamental analysis module provides a way to measure Epigenomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Epigenomics pink sheet.
Epigenomics |
Epigenomics AG Company Current Valuation Analysis
Epigenomics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Epigenomics Current Valuation | (9.71 M) |
Most of Epigenomics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Epigenomics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Epigenomics AG has a Current Valuation of (9.71 Million). This is 100.07% lower than that of the Healthcare sector and 100.12% lower than that of the Diagnostics & Research industry. The current valuation for all United States stocks is 100.06% higher than that of the company.
Epigenomics AG Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Epigenomics's current stock value. Our valuation model uses many indicators to compare Epigenomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Epigenomics competition to find correlations between indicators driving Epigenomics's intrinsic value. More Info.Epigenomics AG is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Epigenomics' earnings, one of the primary drivers of an investment's value.Epigenomics Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Epigenomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Epigenomics could also be used in its relative valuation, which is a method of valuing Epigenomics by comparing valuation metrics of similar companies.Epigenomics is currently under evaluation in current valuation category among its peers.
Epigenomics Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (15.90) % | |||
| Current Valuation | (9.71 M) | |||
| Shares Outstanding | 4.09 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 4.86 % | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 0.39 X | |||
| Price To Sales | 10.64 X | |||
| Revenue | 6.2 M | |||
| Gross Profit | 6.07 M | |||
| EBITDA | (1.94 M) | |||
| Net Income | (2.43 M) | |||
| Cash And Equivalents | 15.77 M | |||
| Cash Per Share | 0.96 X | |||
| Total Debt | 966 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.88 X | |||
| Book Value Per Share | 3.41 X | |||
| Cash Flow From Operations | (4.15 M) | |||
| Earnings Per Share | (0.30) X | |||
| Target Price | 8.59 | |||
| Number Of Employees | 36 | |||
| Beta | 1.08 | |||
| Market Capitalization | 6.01 M | |||
| Total Asset | 24.66 M | |||
| Retained Earnings | (62 M) | |||
| Working Capital | 5 M | |||
| Current Asset | 10 M | |||
| Current Liabilities | 5 M | |||
| Z Score | 0.8 | |||
| Net Asset | 24.66 M |
About Epigenomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Epigenomics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Epigenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Epigenomics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Epigenomics Pink Sheet
Epigenomics financial ratios help investors to determine whether Epigenomics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Epigenomics with respect to the benefits of owning Epigenomics security.